FDA label b9fe23f0-ce84-42d7-99a8-3a246ead86d5

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
f7036088-40c5-444a-80d4-cead603d2f2e
SPL ID
b9fe23f0-ce84-42d7-99a8-3a246ead86d5
Version
2
Effective date
2012-09-25
Source export date
2026-10-12
Source partition
11
Source file
https://download.open.fda.gov/drug/label/drug-label-0011-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-12/a497e765d824a2e2aa9e88d5f0eea2aae9dcba363989e5f163395cda5c3c9dd8/drug-label-0011-of-0014.json.zip
Source manifest SHA-256
7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run
20261013T011858Z
Imported at
2026-10-13 02:47:42

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings

WARNINGS Sympathomimetic amines should be used with caution in patients with hypertension, diabetes mellitus, ischemic heart disease, increased intraocular pressure, hyperthyroidism, renal impairment, or prostatic hypertrophy (see CONTRAINDICATIONS ). Sympathomimetic amines may produce central nervous system stimulation with convulsions or cardiovascular collapse with accompanying hypotension.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

ADVERSE REACTIONS Fexofenadine Hydrochloride In a placebo-controlled clinical study in the United States, which included 570 subjects with seasonal allergic rhinitis aged 12 years and older receiving fexofenadine hydrochloride tablets at doses of 120 or 180 mg once daily, adverse events were similar in fexofenadine hydrochloride and placebo-treated subjects. The following table lists adverse experiences that were reported by greater than 2% of subjects treated with fexofenadine hydrochloride tablets at doses of 180 mg once daily and that were more common with fexofenadine hydrochloride than placebo. Once daily dosing with fexofenadine hydrochloride tablets at rates of greater than 2% Adverse experience Fexofenadine 180 mg once daily (n=283) Placebo (n=293) Headache 10.6% 7.5% Upper Respiratory Tract Infection 3.2% 3.1% Back Pain 2.8% 1.4% Events that have been reported during controlled clinical trials involving subjects with seasonal allergic rhinitis at incidences less than 1% and similar to placebo and have been rarely reported during postmarketing surveillance include: insomnia, nervousness, and sleep disorders or paroniria. In rare cases, rash, urticaria, pruritus and hypersensitivity reactions with manifestations such as angioedema, chest tightness, dyspnea, flushing and systemic anaphylaxis have been reported. Pseudoephedrine Hydrochloride Pseudoephedrine hydrochloride may cause mild CNS stimulation in hypersensitive patients. Nervousness, excitability, restlessness, dizziness, weakness, or insomnia may occur. Headache, drowsiness, tachycardia, palpitation, pressor activity, cardiac arrhythmias and ischemic colitis have been reported. Sympathomimetic drugs have also been associated with other untoward effects such as fear, anxiety, tenseness, tremor, hallucinations, seizures, pallor, respiratory difficulty, dysuria, and cardiovascular collapse.

adverse reactions table

<table width="80%" ID="icd0853b0-fcfc-42a9-817b-4f47c4e928a0"> <caption>Once daily dosing with fexofenadine hydrochloride tablets at rates of greater than 2%</caption> <col align="left" width="45%" valign="top"/> <col align="center" width="35%" valign="top"/> <col align="center" width="20%" valign="top"/> <thead> <tr> <th> <content styleCode="bold italics">Adverse experience</content> </th> <th> <content styleCode="bold italics">Fexofenadine 180 mg once daily (n=283)</content> </th> <th> <content styleCode="bold italics">Placebo (n=293)</content> </th> </tr> </thead> <tbody> <tr> <td>Headache</td> <td>10.6%</td> <td>7.5%</td> </tr> <tr> <td>Upper Respiratory Tract Infection</td> <td>3.2%</td> <td>3.1%</td> </tr> <tr> <td>Back Pain</td> <td>2.8%</td> <td>1.4%</td> </tr> </tbody> </table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.